Institutional Investment Pitches
Explore thousands of hedge fund pitches, high-conviction equity research memos, and portfolio manager commentary extracted from quarterly letters.
Explore thousands of hedge fund pitches, high-conviction equity research memos, and portfolio manager commentary extracted from quarterly letters.
Boston Scientific detracted after growth slowed in two of its key businesses, its electrophysiology franchise and Watchman heart implant, due to growing competition and mixed clinical trial results. We exited the...
— Andrew Choi & Shivani Vohra
Full equity research memos, financial breakdowns, and hedge fund thesis write-ups are reserved for BSD Research ($50/mo) and Pro subscribers.
Already a Research or Pro subscriber? Sign In
Other investors who've written on Boston Scientific
Boston Scientific ($BSX) represents 5.7% of the fund's portfolio. The company designs,...
A highly innovative pipeline in cardiology and other medtech spaces continues to fuel double-digit revenue growth and operating leverage. Recent stock declines...
More institutional theses from Parnassus Growth Equity Fund
GE Vernova is a global industrial leader supplying heavy-duty gas turbines, electrification systems, and electrical grid infrastructure. The manager maintains...
Comfort Systems USA is a premier national mechanical, electrical, and plumbing (MEP) contracting specialist focused on complex commercial and industrial building projects. The manager holds...